

# SPHHP Research Activities Newsletter

University at Buffalo

January 2020

## IN THE NEWS

### Congratulations to the Following Awardees!



**Jessica Kruger**, Clinical Assistant Professor of Community Health and Health Behavior, is PI on a new award from Top Hat. The project will assess the utility and effectiveness of tailored and non-tailored messages to students based on weekly performance in class. Student perceptions of this educational intervention will be assessed along with drop, fail, withdraw, and resign (DFWR) rates for the courses utilizing this and compared to previous semesters when this methodology was not utilized.



**Lucia Leone**, Assistant Professor of Community Health and Health Behavior, is PI on a new award from the AARP Foundation for the project entitled, *Pilot of the Senior Mobile Market Loyalty Program*. The project will pilot test a mobile market-based fruit and vegetable incentive program, the Senior Mobile Market Loyalty Program, for lower-income seniors. Eligible seniors will receive a discount off their purchase any time they visit the mobile market. The program's goal is to help improve food security and diet of lower-income seniors.



**Elizabeth Mietlicki-Baase**, Assistant Professor of Exercise and Nutrition Sciences, is PI on a new award from UB's Center for Ingestive Behavior Research for the project entitled, *Role of Mesolimbic Receptor Activity-modifying Protein 1 in Amylin-mediated Energy Balance Control*. The study will examine the physiological mechanisms underlying the ability of amylin, a peptide that suppresses feeding and weight gain, to control food intake.



**Kimberly Naus**, Director of CAT Client Services, received a continuation award from the New York State Justice Center for the Protection of People with Special Needs for the project entitled, *Technology Related Assistance for Individuals with Disabilities (TRAID) Program*. TRAID supports the development of state-wide consumer-responsive technical assistance programs for persons with disabilities.



**Ekaterina Noyes**, Professor of Epidemiology and Environmental Health, is Co-I on a continuation award (PI: Jeffrey Mador, Medicine) from Roswell Park Comprehensive Cancer Center/NIH for the project entitled, *Preoperative Respiratory Muscle Training to Prevent Postoperative Pulmonary Complications Undergoing Resection for Lung Cancer*. The study will continue to determine how a home-based program designed around strengthening the respiratory muscles will improve postoperative health.

#### Inside this issue:

In the News	1-2
Grant Clinic	2-4
NIH Funding	
RFA	4-6
PAR	6-7
DOD—Dept. of Army	7
Admin. Comm. Living	8
Foundations:	
Robert Wood Johnson	8
Individual Actions of Sustainability	8



**Todd Rideout**, Associate Professor of Exercise and Nutrition Sciences, is Co-I on a new award from the American Egg Board (PI: Xiaozhong Wen, Pediatrics) for the project entitled, *Effects of Infant Egg Consumption on Child Health and Cognition Development*. Using existing data from two US longitudinal birth cohorts that tracked mother-child dyads from pregnancy to adolescence, the study will examine how infant egg consumption (age of introduction and frequency of intake) influences physical growth, obesity, cardio-metabolic health, risk of allergy, and cognition development in mid-childhood and adolescence.

## GRANT CLINIC

### **REMINDER: ORCID iDs Now Required for Fellowship and Career Development Applicants**

ORCID iDs **are required** for PD/PIs on individual fellowship and career development applications submitted for due dates on or after **January 25, 2020**. Everyone is encouraged, from graduate students to senior scientists, to [register for an ORCID account](#) and [link it to their eRA Commons personal profile](#). The eRA systems will check the PD/PI eRA Commons ID on all submitted fellowship and career development applications. If there is not a linked ORCID iD, an error will be generated, preventing the application from moving forward to NIH for consideration.

### **Update to NSF Approved Biosketch and Current/Pending Formats**

NSF is partnering with NIH to use [SciENcv](#) as an NSF-approved format for use in preparing both the Biosketch and Current and Pending Support Sections of a proposal. The approved format will be required upon the implementation of the revised 2020 Proposal and Award Policies and Procedures Guide (PAPPG). NSF is encouraging applicants to begin using SciENcv for preparation of biosketches now.

### **NIH Notices**

#### [NOT-OD-20-043](#)

##### **Revised Grants Policy Statement (NIHGPS) (Rev. December 2019) for FY 2020**

The NIHGPS provides both up-to-date policy guidance that serves as NIH standard terms and conditions of awards for grants and cooperative agreements, and extensive guidance to those who are interested in pursuing NIH grants. While the revision does not introduce any new material, it incorporates new and modified requirements and clarifies certain policies and changes in statutes and regulations. The document is available [here](#).

#### [NOT-OD-20-018](#)

##### **Update to NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding**

NIH has updated its HIV research priorities. The highest overarching priorities effective FY 2021 to FY 2025 are: 1) reduce the incidence of HIV/AIDS, including the development of safe and effective HIV/AIDS vaccines and microbicides; 2) develop the next generation of HIV therapies with improved safety and ease of use; 3) discover a cure for HIV/AIDS; and 4) reduce HIV-associated comorbidities and coinfections. Please refer to the NIH notice for examples of research that is aligned with the priority areas.

### **Requests for Information**

#### [NOT-TW-19-008](#)

##### **Learning from the Transfer of HIV Interventions from Low- and Middle-Income Countries (LMICs) to the United States: Informing the Plan for America to End the HIV Epidemic**

NIH is soliciting examples of interventions in HIV prevention, care or treatment that were developed in LMICs and have been transferred and attempted to be implemented, both successfully and unsuccessfully, in the U.S. The goal is to harness these lessons learned to develop a scientific research agenda to inform the initiative to end the U.S. HIV epidemic. NIH plans to host a workshop to highlight successful and unsuccessful intervention transfers that have been identified through this RFI and other means. **Responses are due by February 15, 2020.**

#### [NOT-LM-20-003](#)

##### **ClinicalTrials.gov Modernization**

NLM is embarking on a modernization initiative to update the technological infrastructure underlying ClinicalTrials.gov, enhance its public-facing components, and deliver a modern user experience with a platform and services that continue to accommodate growth and enhance efficiency. Please see the NIH notice for topic areas that NLM is requesting public comment on. Responses must be submitted electronically to the link provided in the NIH Notice by **March 14, 2020.**

## Notices of Special Interest

If you will be applying under any of the special interest topics listed below, please indicate so, including the NIH Notice number, in the Comments box of the RAS Questionnaire. The RAS staff will ensure that this information is included with the application to NIH.

### NOT-OD-20-048 – Research on the Health of Women of Understudied, Underrepresented, and Underreported Populations (U3)

The Office of Research on Women's Health announces the availability of administrative supplements to support research highlighting health disparities among women in the US who are underrepresented, understudied, and underreported in biomedical research. The proposed research must address at least one objective from the strategic goals 1, 2, or 3 of the 2019-2023 [Trans-NIH Strategic Plan for Women's Health Research](#) "Advancing Science for the Health of Women." Please refer to the NIH notice for areas of research interest and additional requirements.

NOT-OD-20-048 for be included in box 4B of the SF424 application.

**Application Due Dates:** January 28, 2020 and January 21, 2021.

### NOT-OD-20-049 – Administrative Supplements for Research on Sex/Gender Influences

The Office of Research on Women's Health announces the availability of administrative supplements to support research highlighting the impact of sex and gender influences in human health and illness. The most robust experimental designs include consideration of both sex and gender; therefore, applications proposing to investigate the influence of both sex and gender factors are highly encouraged. The proposed research must address at least one objective from the five strategic goals of the 2019-2023 [Trans-NIH Strategic Plan for Women's Health Research](#) "Advancing Science for the Health of Women". Please refer to the NIH notice for areas of research interest and additional requirements. NOT-OD-20-049 must be included in box 4B of the SF424 application.

**Application Due Dates:** January 31, 2020 and January 25, 2021

### NOT-DK-20-003 – Addressing Health Disparities in NIDDK Diseases

The overall objective of this NOSI is to understand and mitigate health disparities in the development, diagnosis, and treatment of diseases of high priority to the NIDDK. Research approaches may include metabolic, genetic, genomic, proteomic, proteogenomics, behavioral, clinical and/or epidemiologic studies in representative populations. Please refer to the Notice for topics of interest. Applications for this initiative should use the parent R01, clinical trial not allowed ([PA-19-056](#)). NOT-DK-20-003 must be included in box 4B of the SF424 application.

**Application Due Dates:** Standard dates apply; **Expiration Date:** January 8, 2023.

### NOT-DA-20-009 – Modeling Social Contagion of Substance Use Epidemics

NIDA is interested in projects that leverage big data sets and utilize machine learning algorithms to gain new knowledge related to the behaviors associated with substance use disorders and that will facilitate the prediction, prevention and response to epidemics of substance use disorders. Analyses should involve large datasets and data science approaches to develop computational models of social networks to examine how substance use/misuse and peer use/misuse is propagated among social networks. Please see the NIH notice for additional information. NOT-DA-20-009 must be included in box 4B of the SF424 application.

**Application Due Dates:** Standard dates apply; **Expiration Date:** January 8, 2023.

### NOT-OD-20-054 – Administrative Supplements to Promote Research Continuity and Retention of NIH Mentored Career Development (K) Award Recipients and Scholars

The supplement is intended to promote the continuity of the career development research project during a period in which the PD/PI experiences critical life events which have the potential to impact research progress or potential productivity. For the purposes of this program, childbirth, adoption, and primary caregiving responsibilities of an ailing spouse, child, partner, or a member of the immediate family during the project period are critical life events that would qualify for consideration. Please refer to the NIH notice for eligible activity codes. Supplement requests must be submitted through the parent announcement, [PA-18-591](#), or its subsequent reissued equivalent. NOT-OD-20-054 must be included in box 4B of the SF424 application.

### NOT-OD-20-007 – Preclinical and Clinical Studies of the Interactions of Opioids and Stimulants

NIDA will support mechanism-based approaches that will 1) elucidate factors and mechanisms mediating the toxic effects of concomitant opioid and stimulant use and 2) point to new therapeutic targets and prevention strategies. This notice applies to due dates on or after June 5, 2020. Please see the NIH notice for additional information, as well as appropriate FOAs to apply to. NOT-OD-20-007 must be included in box 4B of the SF424 application.

### [NOT-OD-20-012](#) – Biomarkers and Biotypes of Drug Addiction

NIDA has a special interest in research project applications that focus on discovery, development, and validation of drug addiction biomarkers, biosignatures and elucidation of substance use disorder biotypes, with an emphasis on machine learning and artificial intelligence (AI) based analytical approaches. Applications should be submitted under the following parent applications: PA-19-055; PA-19-056; PA-19-091. This notice applies to due dates on or after February 25, 2020 through May 7, 2023. NOT-OD-20-012 must be included in box 4B of the SF424 application.

### Notices of Intent to Publish a Funding Opportunity Announcement

#### [NOT-AT-20-005](#)

Re-issuance for HEAL Initiative: Pragmatic and Implementation Studies for the Management of Pain to Reduce Opioid Prescribing (PRISM) (UG3/UH3); anticipated release January 2020; expected due date March 2020

#### [NOT-CA-20-015](#)

Strengthening Institutional Capacity to Conduct Global Cancer Research (D43); anticipated release winter 2020; expected due dates spring 2020 and winter 2021.

## NIH FUNDING OPPORTUNITIES

### REQUESTS FOR APPLICATIONS (RFA)

#### March Due Dates

#### [RFA-DK-19-019 \(R01\)](#) – clinical trial optional

##### **Food as Medicine: Food Insecurity and HIV-related Comorbidities, Coinfections, and Complications within the Mission of the NIDDK**

This FOA seeks US domestic research projects that address how food insecurity effects HIV comorbidities, coinfections, and complications (CCCs) within the mission of the NIDDK. The approaches may address the pathways linking food insecurity and the development or exacerbation of CCCs; or they may evaluate the mechanisms whereby interventions that alleviate food insecurity improve CCCs. These mechanisms could be related to nutritional inadequacies or patient health-related behaviors. **Application Due Date:** March 9, 2020

#### [RFA-DA-20-022 \(R01\)](#) – clinical trial optional

##### **Assessing the Effects of Cannabinoids on HIV-Induced Inflammation**

This FOA supports basic science and preclinical research to determine the biological mechanisms underlying the effects of cannabinoids and the endocannabinoid system on HIV-associated persistent inflammation and its consequent effects on nervous system function. Projects submitted in response to this FOA must include expertise and resources in both areas of HIV/AIDS and addiction science. **Application Due Date:** March 11, 2020

#### [RFA-AI-19-067 \(U01\)](#) – clinical trial required

##### **Digital, Limited Interaction Trials and Epidemiology (D-LITE): Targeting HIV Incidence in the United States**

This FOA solicits applications to conduct large-scale digital clinical trials to test whether digitally-delivered HIV prevention interventions can reduce HIV incidence among U.S. men who have sex with men (MSM) and/or transgender women and men. The major goal is to support investigators who will use innovative electronic methods to recruit and retain large samples of persons at high risk of HIV infections, conduct digitally-delivered interventions that promote HIV risk reduction and pre-exposure prophylaxis (PrEP) use, and assess the resulting impact on HIV incidence through mailed HIV test kits or other remote means. **Application Due Date:** March 20, 2020

#### [RFA-AA-20-006 \(R01\)](#) – clinical trial optional

##### **Impact of Alcohol on the Onset and Progression of Alzheimers Disease and Its Related Dementias**

NIAAA and NIA solicit research projects that combine diverse expertise and use innovative approaches to investigate mechanisms by which alcohol affects brain aging processes to produce dementias and influences development of Alzheimer's disease. This FOA strongly encourages collaborations between alcohol researchers and experts in Alzheimer's disease and its related dementia research. **Application Due Date:** March 24, 2020

## Multiple Due Dates

[RFA-NS-20-008 \(R41/R42\)](#); [RFA-NS-20-010 \(R43/R44\)](#) - clinical trial required  
[RFA-NS-20-009 \(R41/R42\)](#); [RFA-NS-20-011 \(R43/R44\)](#) – clinical trial not allowed

### **HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management**

These FOAs aim to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management. They are focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies. **Application Due Dates:** April 7, 2020, September 9, 2020, January 6, 2021, April 6, 2021, September 8, 2021, January 6, 2022, April 6, 2022, and September 8, 2022

[RFA-DA-19-019 \(R43/R44\)](#) – clinical trial optional

[RFA-DA-19-020 \(R41/R42\)](#) – clinical trial optional

### **America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis**

These FOAs invite applications from US small business concerns to develop technologies to provide science-and research-based solutions to the opioid emergency. **Application Due Dates:** April 9, 2020, September 8, 2020, April 9, 2021, September 8, 2021

[RFA-CA-20-019 \(R21\)](#) – **Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research**

[RFA-CA-20-020 \(R33\)](#) – **Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research**

This FOA solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens.

**Application Due Date:** May 28, 2020; September 29, 2020

[RFA-NS-19-043 \(K99/R00\)](#) – clinical trial not allowed; [RFA-NS-19-044 \(K99/R00\)](#) – independent clinical trial required

### **BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity**

This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The BRAIN Initiative is aimed at revolutionizing our understanding of the human brain. By accelerating the development and application of innovative technologies, researchers will be able to produce a new dynamic picture of the brain that, for the first time, will show how individual cells and complex neural circuits interact in both time and space.

**Application Due Dates:** June 10, 2020; October 9, 2020; February 10, 2021; June 9, 2021; October 6, 2021; February 10, 2022; June 8, 2022; October 11, 2022

[RFA-CA-19-034 \(P20\)](#) – clinical trial optional

### **Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities**

The P20 grants will support feasibility and planning activities to build comprehensive cancer health disparities research programs. All applications must propose translational research that will contribute to improved prevention, early detection, diagnosis, and/or treatment of cancers found to disproportionately affect specific racial/ethnic minority populations. **Application Due Dates:** June 19, 2020, and October 18, 2020

[RFA-OD-19-028 \(R01\)](#) – clinical trial optional

### **Tobacco Regulatory Science**

This FOA supports biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP).

**Application Due Dates:** July 17, 2020, February 13, 2021

[RFA-OD-19-022 \(R21\)](#) – clinical trial not allowed

### **Secondary Analyses of Existing Datasets of Tobacco Use and Health**

This FOA supports research proposing the innovative analysis of existing (publicly available) nationally representative U.S. cross-sectional and longitudinal data, to investigate novel scientific ideas and/or to generate new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP).

**Application Due Dates:** July 20, 2020, March 8, 2021

[RFA-OD-19-021 \(R21\)](#) – clinical trial not allowed

**Maximizing the Scientific Value of Existing Biospecimen Collections: Scientific Opportunities for Exploratory Research**

This FOA invites applications to stimulate exploratory research relevant to the mission of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP) using existing (publicly available) biospecimens currently stored in repositories in the United States. Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. **Application Due Dates:** August 7, 2020, March 8, 2021

[RFA-HL-19-024 \(R25\)](#) – clinical trial not allowed

**Short-Term Research Education Program to Increase Diversity in Health-Related Research**

The over-arching goal of this program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce by providing research experiences and related opportunities that enrich the pool of individuals from nationally underrepresented groups who will be available to compete for research opportunities in the mission areas of importance to NHLBI. **Application Due Dates:** September 10, 2020, February 26, 2021

[RFA-HL-19-025 \(K01\)](#) – clinical trial required; [RFA-HL-19-026 \(K01\)](#) – clinical trial not allowed

**Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research**

Applications are invited to enhance the pool of highly trained investigators from diverse backgrounds, including those from groups underrepresented in research areas of interest to the NHLBI. These FOAs are targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. **Application Due Dates:** October 9, 2020, February 11, 2021

[RFA-ES-19-011 \(R21\)](#) – clinical trial not allowed

**Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences**

This FOA supports novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented.

**Application Due Dates:** Monthly due dates starting November 1, 2019; please refer to the RFA.

## Program Announcements Reviewed by an Institute (PAR)

[PAR-20-078 \(R21\)](#) – clinical trial not allowed

**Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders**

The goal of this FOA is to stimulate the use of existing human datasets for well-focused secondary analyses to investigate novel scientific ideas or new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the NHLBI mission. This FOA actively supports the use of existing database resources to conduct additional analyses secondary to a project's originally-intended primary purpose. **Application Due Dates:** February 26, 2020, October 28, 2020, February 26, 2021, October 28, 2021, February 26, 2022, October 28, 2022

[PAR-20-070 \(R21/R33\)](#) – clinical trial optional

**Research Infrastructure Development for Interdisciplinary Aging Studies**

Applications submitted to this FOA should propose development of research infrastructure to advance specific topics in aging science that require interdisciplinary partnerships or collaborations. The range of disciplines included in the application should be appropriate to the scientific goals of the proposed collaboration. This FOA is intended to support establishment of new interdisciplinary collaborations or development of existing interdisciplinary collaborations in significantly new directions. For existing collaborations, reviewers will evaluate closely whether the application represents a substantial development in scientific focus as opposed to simply maintaining existing operations.

**Application Due Dates:** Standard dates apply; **Expiration Date:** November 17, 2022

[PAR-20-071 \(R33\)](#) – clinical trial optional

**Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies**

This FOA invites applications that propose to support advanced-stage development and utilization of novel research infrastructure to advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Exploratory/Developmental Grants Phase II mechanism to provide support for expanded activities. Applicants are expected to have an existing research infrastructure developed, either through PA-12-064 or with other NIH or non-NIH support. Through this award, investigators will develop a mature and sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.

**Application Due Dates:** Standard dates apply; **Expiration Date:** November 17, 2022

## U.S. DEPARTMENT OF DEFENSE

### Department of the Army—USAMRRA

#### DOD Beast Cancer Breakthrough Awards

The Breakthrough Awards support promising research that has high potential to lead to or make breakthroughs in breast cancer.

#### [W81XWH-20-BCRP-BTA12](#)

**Level 1** (\$450,000 Single PI; \$750,000 Partnering PI) – innovative, high-risk/high-reward research that is in the earliest stages of idea development or is an untested theory that addresses an important problem. Preliminary data are not required.

**Level 2** (\$1M Single PI; \$1.5M Partnering PI) – preclinical research that is already supported by substantial preliminary or published data and strongly validates clinical translation in a well-defined context within the breast cancer landscape.

**Level 2, Population Science and Prevention Studies** (\$1.5M Single PI; \$2M Partnering PI) – with compelling justification, these studies may request higher levels of funding and an additional year in the period of performance.

Applications submitted in response must address at least one of the overarching challenges listed in the FOA.

**Application Due Dates:** Pre-Application: March 12, 2020 Application: March 26, 2020

#### [W81XWH-20-BCRP-BTA3](#)

**Level 3** (\$3M Single PI; \$4M Partnering PI) – advanced translational studies with a high degree of project readiness. Where relevant, proof of availability of and access to necessary data, human samples, cohort(s) and/or critical reagents must be provided. Small scale clinical trials may be appropriate. Applications submitted in response must address at least one of the overarching challenges listed in the FOA.

**Application Due Dates:** Pre-Application: March 13, 2020 Invited Application: June 24, 2020

#### [W81XWH-20-BCRP-BTA4](#)

**Level 4** (\$10M) – large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer. Human clinical trials are required. PIs are expected to have experience and demonstrated ability in successfully leading large-scale projects. Applications submitted in response must address at least one of the overarching challenges listed in the FOA.

**Application Due Dates:** Pre-Application: March 13, 2020 Invited Application: June 24, 2020

#### [W81XWH-20-BCRP-INNOV](#)

#### Breast Cancer Research Program Innovator Award

The Innovator Award supports visionary individuals who have demonstrated exceptional creativity, innovative work, and paradigm-shifting leadership in any field including, but not limited to, breast cancer. The PI must maintain a 50% dedication of their full-time professional effort during the award period to breast cancer. The award maximum is \$7M in direct costs.

**Application Due Dates:** Pre-Application: March 13, 2020 Invited Application: June 24, 2020

## ADMINISTRATION FOR COMMUNITY LIVING

[HHS-2020-ACL-NIDILRR-SFGE-0375](#)

### Switzer Research Fellowships Program

This program supports highly qualified individuals to conduct research on the rehabilitation of individuals with disabilities. The program provides two categories of research fellowships: Merit Fellowships and Distinguished Fellowships:

Merit Fellowship: an individual must be in the earlier stages of his or her career in research and have either advanced professional training or experience in independent study in an area which is directly pertinent to disability and rehabilitation.

Distinguished Fellowship: an individual must have seven or more years of research experience in subject areas, methods, or techniques relevant to research on rehabilitation, independent living and other experiences and outcomes of individuals with disabilities, and must have a doctorate, other terminal degree, or comparable academic qualifications.

The length of the fellowships is 12 months. Only individuals, not Institutions, are eligible to apply.

**Application Due Date:** March 3, 2020

## FOUNDATION FUNDING OPPORTUNITIES

### Robert Wood Johnson Foundation

The following programs are designed to build on leadership skills and connect with other innovators to advance creative, action-oriented solutions to our nation's most entrenched challenges to health. Participants receive financial support and do not need to relocate. The programs are designed for people working or pursuing research full-time.

Clinical Scholars is seeking teams of health care professionals from all disciplines, including occupational therapists and physical therapists. Interdisciplinary teams of health care providers will collaborate to tackle complex health problems in their communities and build a Culture of Health nationwide. The program is 3 years and scholars can receive up to \$525,000 for a five-person team. **Application Due Date:** March 11, 2020

Culture of Health Leaders is a leadership development opportunity for people working in every field and profession who want to use their influence to advance health, equity, diversity, and inclusion. The program is 3 years and participants will receive an annual stipend of \$20,000, which can be used to cover salary, living expenses, and more. **Application Due Date:** February 19, 2020

Health Policy Research Scholars is looking for second- and third-year doctoral students from all fields that have a direct impact on health policy. The goal of the program is to train doctoral students to use their discipline-based research training to advance health equity to build a Culture of Health. Students from underrepresented populations and/or marginalized backgrounds, are eligible to apply. Scholars will receive an annual stipend of up to \$30,000 for four years or until they've completed their doctoral program (whichever is sooner).

**Application Due Date:** March 11, 2020

Interdisciplinary Research Leaders is looking for teams of researchers and community partners focused on community environment and health or families and child health. These teams will use the power of applied research to accelerate that work and advance health and equity. The program is 3 years and each person will receive an annual stipend of \$25,000 and a one-time research grant of up to \$125,000 per team for salary, research costs, and more.

**Application Due Date:** March 11, 2020

### Individual Actions for Sustainability Change a Light



*LED lightbulbs use up to 80% less energy than conventional incandescent. They're also cheaper in the long run: A 10-watt LED that replaces a traditional 60-watt bulb will save \$125 over the lightbulb's life.*